Q-omics provides the consensus-scored POGLUT3 profile across patient tissues and cancer cell-line models. POGLUT3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, POGLUT3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, POGLUT3 protein abundance shows 27,112 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BLCA, KIRC, and PDAC as cancer lineages where POGLUT3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POGLUT3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POGLUT3 survival associations across molecular data types. POGLUT3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POGLUT3 RNA expression–survival associations across cancer types. High POGLUT3 expression shows unfavorable associations in BLCA, KIRP, LGG, LIHC and MESO, but favorable associations in KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for POGLUT3 RNA expression.
This table summarizes POGLUT3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for POGLUT3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POGLUT3 shows lower tumor expression in UCEC and higher tumor expression in KIRC, HNSC, LUAD, CHOL and LUSC. The KIRC box plot shows higher POGLUT3 RNA expression in tumor versus normal tissue (log2 FC = +1.137, t-test p < 0.001).
This table shows molecular features associated with POGLUT3 in patient tissues and cancer cell lines. In patient samples, POGLUT3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, POGLUT3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BREAST.
